<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A3</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A3</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents – A3</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lloyd Axelrod, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">ANSWER</span><span class="headingEndMark"> — </span>Incorrect.</p><p><a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">Sitagliptin</a> was the first of a class of agents marketed for the treatment of diabetes, the dipeptidyl peptidase 4 (DPP-4) inhibitors. Agents in this class inhibit the breakdown of endogenous glucagon-like peptide 1 (GLP-1) and other incretins. Thus, their biological effects are similar, but not identical, to those of GLP-1 agonists. (See  <a class="medical medical_review" href="/d/html/96015.html" rel="external">"Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus", section on 'Patient selection'</a>.)</p><p>Like the GLP-1 receptor agonists, DPP-4 inhibitors are indicated for patients with type 2 diabetes but not those with type 1 diabetes. </p><p>DPP-4 inhibitors are given orally. For all DDP-4 inhibitors except <a class="drug drug_general" data-topicid="16490" href="/d/drug information/16490.html" rel="external">linagliptin</a>, a dose adjustment is required in patients with impaired kidney function  (<a class="graphic graphic_table graphicRef141217" href="/d/graphic/141217.html" rel="external">table 1</a>). They are relatively expensive. In postmarketing reports, DPP-4 inhibitors have been associated with hypersensitivity reactions including anaphylaxis, angioedema, and blistering skin conditions, including Stevens-Johnson syndrome. They have also been associated with severe joint pains.</p><p>The US Food and Drug Administration (FDA) issued an alert about a possible association of incretin-based drugs such as <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a> (and <a class="drug drug_general" data-topicid="9005" href="/d/drug information/9005.html" rel="external">exenatide</a>) with acute pancreatitis based upon a review of 30 postmarketing reports, in some of which a causal relationship between these agents and acute pancreatitis was suspected. The FDA and the European Medicines Agency now agree that there is insufficient evidence to confirm an increased risk of pancreatitis or pancreatic cancer with the use of GLP-1-based therapies [<a href="#rid1">1</a>]. Pancreatitis continues to be considered a risk associated with these drugs. Concerns remain, and monitoring for and reporting of pancreatic adverse effects continues.</p><p><a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">Sitagliptin</a> has not been shown to be superior to any other single pharmacologic agent in direct comparison. The addition of sitagliptin to a single oral agent has not been shown to be superior to other two-agent combinations, such as <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and a sulfonylurea.</p><p>Because of its relatively high cost and weak therapeutic effect, <a class="drug drug_general" data-topicid="9482" href="/d/drug information/9482.html" rel="external">sitagliptin</a> is typically not recommended for routine use. It may have an occasional role as a third oral agent in patients with a modest elevation of the glycated hemoglobin (A1C) level when maximum tolerated doses of <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> and another agent have not achieved glycemic goals.</p><p>Return to the beginning to try again. (See  <a class="medical medical_review" href="/d/html/4176.html" rel="external">"Interactive diabetes case 16: A 61-year-old patient with uncontrolled type 2 diabetes on two oral agents"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014; 370:794.</a></li></ol></div><div id="topicVersionRevision">Topic 4212 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24571751" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pancreatic safety of incretin-based drugs--FDA and EMA assessment.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
